KPS "Secures Blood CTC Detection Marker... International Patent Application Next Month"
[Asia Economy Reporter Jang Hyowon] KPS Bio Division announced on the 20th that it has secured a 'Circulating Tumor Cell (CTC)-specific biomarker' capable of selectively isolating cancer cells from blood. This biomarker is 'DSG2 (Desmoglein2)', one of the epithelial cell membrane proteins, and research indicates that overexpression of DSG2 in cancer cells promotes tumor growth and influences cancer metastasis.
According to KPS, Kyung Hee University Industry-Academic Cooperation Foundation, the patent applicant for the biomarker, recently transferred all rights (change of application) for the 'method of detecting circulating tumor cells using DSG2' to KPS. The company plans to consecutively file international patents (PCT) next month.
KPS plans to collaborate extensively with Kyung Hee University College of Pharmacy to develop DSG2 as a CTC biomarker for EpCAM (Epithelial Cell Adhesion Molecule) negative CTCs. The Kyung Hee University research team explained that utilizing DSG2 for CTC isolation can detect CTCs that could not be identified using the conventional biomarker EpCAM.
Lee Jaehang, Executive Director of KPS Bio Division, stated, "We introduced the patent for DSG2 to develop CTC isolation technology, which is considered a direct cause of cancer metastasis, and are also developing additional meaningful biomarkers to advance the technology."
He added, "The liquid biopsy market, including CTC-based molecular and immunodiagnostics, has high growth potential and allows frequent monitoring, making it actively applicable to patient-tailored precision treatment. In particular, it will create significant synergy with our customized anticancer drug development projects."
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [Current State of K-Finance for Foreign Nationals]①From Niche to Core... Banks Go All-In on First-Mover Competition
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Meanwhile, according to the global market research firm Grand View Research, the worldwide liquid biopsy market size is expected to grow from $7.82 billion in 2021 to $19.35 billion by 2028, with an average annual growth rate of 13.5%. The CTC diagnostics market is projected to reach approximately $18.3 billion by 2027, with an average annual growth rate of 11.7%.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
